NASDAQ · Biotechnology

LGVN (LGVN) Stock

$0.61 +1.80% NASDAQ: LGVN Healthcare

Valuation

MetricValue
Price$0.61
Market Cap$12.18M
P/E Ratio-0.58
P/B Ratio2.91
P/S Ratio11.78
EPS (TTM)$-1.29
52-Week High$1.80
52-Week Low$0.47
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-383.33%
ROA-230.00%
ROCE-460.00%
Gross Margin-2300.00%
Operating Margin-2300.00%
Net Margin-18.44%
Debt/Equity0.05
Current Ratio1.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$1.0M$2.0M$1.0M
Operating Profit$-17.0M$-18.0M$-21.0M$-17.0M$-23.0M
Net Profit$-17.0M$-19.0M$-21.0M$-16.0M$-23.0M
EPS$-9.00$-9.00$-10.22$-1.07$-1.29
Op Margin-1336.6%-1476.5%-2966.0%-690.7%-1942.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$43.0M$27.0M$12.0M$26.0M$10.0M
Total Liabilities$5.0M$7.0M$5.0M$4.0M$5.0M
Cash$26.0M$11.0M$5.0M$19.0M$5.0M
Borrowings$3.0M$3.0M$2.0M$1.0M$1.0M

Latest News

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease GlobeNewswire · Jul 13, 2026 Longeveron Names Marie Washburn as CFO MT Newswires · Jul 6, 2026 Longeveron® Appoints Marie Washburn as Chief Financial Officer GlobeNewswire · Jul 6, 2026 New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) GlobeNewswire · Jun 18, 2026 Longeveron Granted SME Status by European Medicines Agency MT Newswires · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-10.0M$-14.0M$-19.0M$-14.0M$-19.0M
Investing Cash Flow$-12.0M$-2.0M$8.0M$-2.0M$-1.0M
Financing Cash Flow$0$-1.0M$5.0M$25.0M$0
Net Cash Flow$25.0M$-15.0M$-6.0M$14.0M$-15.0M
Free Cash Flow$-11.0M$-15.0M$-19.0M$-15.0M$-19.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-129.88%
Quick Ratio3.88
Interest Coverage—
Return 1Y-56.78%
Return 3Y-98.23%
Return 5Y-98.99%

Ownership

Insiders Held9.32%
Institutions Held11.88%
Institutions Float Held13.10%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC542,0322026-03-31
Millennium Management Llc446,7252026-03-31
Blackrock Inc.224,1982026-03-31
Geode Capital Management, LLC203,6182026-03-31
Adar1 Capital Management, LLC 200,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASBP $7.26 +3.13% -0.74 $837601 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%
CRIS $4.69 -4.09% -0.35 $9.14M 0.00%
CTXR $0.57 -9.81% -0.68 $6.37M 0.00%
DARE $1.32 +3.13% -1.94 $12.57M 0.00%

About LGVN

LGVN is led by CEO Stephen H. Willard, employs 25 people, headquartered in US, publicly traded since 2021.

LGVN stock trades at $0.61 with a market capitalization of $12.18M. The stock is valued at a price-to-earnings (P/E) ratio of -0.58, price-to-book of 2.91, price-to-sales of 11.78. Over the past 52 weeks the stock has ranged between $0.47 and $1.80, and currently trades 66.1% below its 52-week high.

On profitability, LGVN generates a return on equity (ROE) of -383.33%, return on capital employed of -460.00%, an operating margin of -2300.00%, a net profit margin of -18.44%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides